Modulation of the renin-angiotensin-aldosterone system in heart failure

Current Atherosclerosis Reports

Volumn 16, Issue 4, 2014, Pages

  George, J ^a   Struthers, A D ^a   Lang, C C ^a,b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Chronic heart failure; Drugs; Novel therapy; Reduced preserved ejection fraction; Renin angiotensin aldosterone blockers; Treatment

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ALDOSTERONE SYNTHASE IHIBITOR; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENKEPHALINASE INHIBITOR; ENZYME INHIBITOR; EPLERENONE; LCI 699; MINERALOCORTICOID ANTAGONIST; OMAPATRILAT; PLACEBO; RAMIPRIL; RENIN INHIBITOR; SPIRONOLACTONE; UNCLASSIFIED DRUG; VALSARTAN; ALDOSTERONE SYNTHASE;

ARTICLE; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GYNECOMASTIA; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MOLECULAR PATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR; CHRONIC DISEASE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; REVIEW;

ALDOSTERONE SYNTHASE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; HEART FAILURE; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84893163336     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0403-7     Document Type: Article

References (68)

1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaborationwith the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803-69.
2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol.
3. McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med. 2010;362(3):228-38.
4. Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and shortterm outcomes among medicare patients hospitalized for heart failure, 1993-2006. Jama. 2010;303(21):2141-7.
5. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65-75.
6. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32(6):670-9.
7. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525-33.
8. The SOLVD. Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med. 1991;325(5):293-302.
9. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north scandinavian enalapril survival study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35.
10. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med. 1992;327(10):669-77.
11. Koitabashi N, Kass DA. Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat Rev Cardiol. 2012;9(3): 147-57.
12. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD investigators. Circulation. 1992;86(2):431-8.
13. Goussev A, Sharov VG, Shimoyama H, et al. Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am J Physiol. 1998;275(2 Pt 2):H626-31. (Pubitemid 128734433)
14. McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation. 2004;110(20): 3281-8. (Pubitemid 39525078)
15. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20): 1893-906. (Pubitemid 37409706)
16. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the losartan heart failure survival study ELITE II. Lancet. 2000;355(9215):1582-7. (Pubitemid 30240502)
17. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003;362(9386): 772-6. (Pubitemid 37093917)
18. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet. 2003;362(9386):767-71. (Pubitemid 37093916)
19. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-75. (Pubitemid 33126822)
20. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59. (Pubitemid 351522739)
21. Kuenzli A, Bucher HC, Anand I, et al. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS One. 2010;5(4):e9946.
22. Bulletin. NP. Dual renin-angiotensin aldosterone system blockade in diabetic nephropathy and increased adverse events. 2012 ; http://www.pbm.va.gov/ vacenterformedicationsafety/nationalpbmbulletin/DualRenin- AngiotensinAldosteroneSystemBlockadeandImpairedRenalFu.pdf. Accessed 4th September 2013
23. Zannad F. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment. Am J Cardiol. 1993;71(3):34A-9A. (Pubitemid 23046410)
24. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. 1999;82(1):57-61. (Pubitemid 29309237)
25. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002;970:89-100. (Pubitemid 35286086)
26. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76(17):1259-65.
27. The RALES. Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (]). Am J Cardiol. 1996;78(8):902-7.
28. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-21. (Pubitemid 36384098)
29. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.
30. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351(6):543-51. (Pubitemid 39025171)
31. Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ. 2010;340:c1768.
32. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R. Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation. 2008;118(16):1643- 50.
33. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly peoplewith chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338-45. (Pubitemid 44453578)
34. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362(9386):777-81. (Pubitemid 37093918)
35. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-67.
36. Lund LH, Benson L, Dahlstrom U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. Jama. 2012;308(20):2108-17.
37. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the aldo-dhf randomized controlled trial. Jama. 2013;309(8):781-91.
38. Nguyen G. Renin, (pro)renin and receptor: an update. Clin Sci (Lond). 2011;120(5):169-78.
39. Moilanen AM, Rysa J, Serpi R, et al. (Pro)renin receptor triggers distinct angiotensin II-independent extracellular matrix remodeling and deterioration of cardiac function. PLoS One. 2012;7(7): e41404.
40. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47(8):515-31. (Pubitemid 351969826)
41. Seed A, Gardner R, McMurray J, et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail. 2007;9(11):1120-7. (Pubitemid 47633316)
42. van Esch JH, Moltzer E, van Veghel R, et al. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens. 2010;28(10):2145-55.
43. Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol. 2008;51(5):519-28.
44. Pitt B, Latini R, Maggioni AP, et al. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the aliskiren observation of heart failure treatment study. Eur J Heart Fail. 2011;13(7):755-64.
45. Solomon SD, Shin SH, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011;32(10):1227-34.
46. Novartis. Novartis announces termination of ALTITUDE study with Rasilez®/Tekturna® in high-risk patients with diabetes and renal impairment. 2011; http://www.novartis.com/newsroom/media-releases/en/2011/ 1572562.shtml. Accessed 1 June 2013
47. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-13.
48. Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the astronaut randomized trial. Jama. 2013;309(11):1125-35.
49. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013;11(38):21.
50. Agency EM. Review started of combined use of renin-angiotensinsystem (RAS)-acting agents. 2013; http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/referrals/Reninangiotensin-system-(RAS)-acting-agents/ human-referral-prac-000026.jsp&mid=WC0b01ac05805c516f.
51. Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the aliskiren trial to minimize OutcomeS in patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail. 2011;13(1):107-14.
52. McMurray JJ, Abraham WT, Dickstein K, Kober L, Massie BM, Krum H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail. 2012;14(4):341-3.
53. Bevan EG, Connell JM, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10(7):607-13.
54. Lang CC, Motwani J, Coutie WJ, Struthers AD. Influence of candoxatril on plasma brain natriuretic peptide in heart failure. Lancet. 1991;338(8761):255.
55. McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol. 1997;43(3):329-32. (Pubitemid 27116076)
56. Kentsch M, Otter W, Drummer C, Notges A, Gerzer R, Muller-Esch G. Neutral endopeptidase 24.11 Inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol. 1996;51(3-4):269-72. (Pubitemid 26422972)
57. Corti R, Burnett Jr JC, Rouleau JL, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation. 2001;104(15):1856-62. (Pubitemid 32963354)
58. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356(9230):615-20. (Pubitemid 30627587)
59. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation. 2002;106(8):920-6. (Pubitemid 34925324)
60. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2):103-11. (Pubitemid 38125125)
61. Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol. 2008;153(5):947-55. (Pubitemid 351328937)
62. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptorneprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401-14.
63. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255-66.
64. Kobalava ZPE, Averkov O. First experience with concomitant AT1 and neprilysin (NEP24.11) Inhibition with LCZ696 in patients with chronic heart failure. Circulation. 2010;122, A19378.
65. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387-95.
66. Mearns BM, Phase II. PARAMOUNT trial of LCZ696. Nat Rev Cardiol. 2012;9(11):612.
67. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007;157(5):545-59. (Pubitemid 350187371)
68. Azizi M, Amar L, Menard J. Aldosterone synthase inhibition in humans. Nephrol Dial Transplant. 2013;28(1):36-43.